Primary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation
|
|
- Baldric Bradley
- 5 years ago
- Views:
Transcription
1 Primary Care Update in Medicine January 31 February 1, 2013 New Management Options for Patients with Atrial Fibrillation Anne B. Curtis, MD, FACC, FHRS, FACP, FAHA Charles and Mary Bauer Professor, Chair, University at Buffalo Department of Medicine CEO and President, UB MD Internal Medicine
2 Disclosures Advisory Board Sanofi Aventis St. Jude Medical Biosense Webster Janssen Pharmaceuticals Bristol Myers Squibb Honoraria Medtronic, Inc. St. Jude Medical Sponsored Research Medtronic, Inc.
3 A 69 year old Caucasian female is referred from her primary care physician s office after she presented with episodic palpitations and was found to have new onset atrial fibrillation. She has a past medical history of hypertension that is well controlled with lisinopril 10 mg daily. There is no history of diabetes mellitus, prior stroke or transient ischemic attack, or cardiovascular disease. What are her CHADS 2 and the CHA 2 DS 2 -VASc scores? a) 1 and 1 b) 1 and 2 c) 1 and 3 d) 1 and 4 Pre-Test Question #1.
4 Pre-Test Question #2. What anti-thrombotic therapy would you initiate to prevent a risk of stroke in this patient? a) None, her risk for stroke is low b) Aspirin 325 mg daily c) Aspirin 325 mg + clopidogrel 75 mg daily d) Warfarin to maintain a therapeutic INR between 2 and 3
5 Pre-Test Question #3. A 73 year old patient is referred for preoperative evaluation for knee replacement surgery because her ECG showed previously undiagnosed atrial fibrillation. She denies cardiovascular symptoms, but she has treated hypertension and a history of myocardial infarction. There is no history of diabetes mellitus, stroke or TIA, or bleeding problems. She denies illicit drug or alcohol use. Her weight is 92.7 kg, Her serum creatinine is 3.2 mg/dl and estimated creatinine clearance is 14 ml/min; liver function is normal. The ECG shows AF with an average ventricular rate of 75 bpm. Echocardiogram shows left ventricular hypertrophy and left atrial enlargement.
6 Which anticoagulation strategy would you recommend? a) Aspirin b) Warfarin c) Dabigatran d) Rivaroxaban
7 Projected Number of Persons With AF (millions) AF Prevalence Is Rapidly Increasing Miyasaka et al. Circulation. 2006;114: Year Current age-adjusted AF incidence Increased age-adjusted AF incidence
8 The Consequences of AF Thromboembolism Stroke: 4.5 increased risk Microemboli: reduced cognitive function Prothrombotic state Hospitalizations Most common arrhythmia requiring hospitalization 2-3 increased risk for hospitalization Reduced QoL Palpitations, dyspnea, fatigue, reduced exercise tolerance Mortality 2 increased risk independent of comorbid CV disease Sudden death in HF and HCM Impaired Hemodynamics Loss of atrial kick Irregular ventricular contractions HF Tachycardia-induced cardiomyopathy HCM=hypertrophic cardiomyopathy. Van Gelder et al. Europace. 2006;8: ; Narayan et al. Lancet. 1997;350: ; Wattigney et al. Circulation. 2003;108: ; Wyse et al. Circulation. 2004;109: ; Favale et al. PACE. 2003;26:
9 What Happens When AF Persists? Structural Remodeling LA and LAA dilatation Fibrosis Electro- physiologic Remodeling Decrease in Ca++ currents Shortening of atrial action potential Increased importance of early activating K + channels: I Kur, I Kto Remodeling explains why AF begets AF
10 Patients in SR (%) Greater SR Maintenance With Earlier Cardioversion AF Duration prior to cardioversion <3 months 3-12 months >12 months 40 a Month 6 Months a P<.02. Dittrich et al. Am J Cardiol. 1989;63: (B).
11 Prevention of Stroke
12 Modification of Stroke Risk CHADS 2 Stratification in AF CHA 2 DS 2 -VASc Risk Factor Score Cardiac failure 1 HTN 1 Age 75 y 1 Diabetes 1 Stroke 2 Total Score Annual Risk of Stroke (%) CHADS 2 CHA 2 DS 2 -VASc Risk Factor Score Cardiac failure 1 HTN 1 Age 75 y 2 Diabetes 1 Stroke 2 Vasc dz (MI, PAD, aortic ath) 1 Age y 1 Sex category (female) 1 CHADS2 Score CHA 2 DS 2 -VASc Risk Intermediate High % 21.7% % Lip GY, Halperin JL. Am J Med 2010;123(6): Olesen JB, et al. Br Med J 2011;342:d124.
13 HAS-BLED Bleeding Risk Score* Letter H A S B L E D Clinical Characteristic HTN Abnormal renal and liver function (1 point each) Stroke Bleeding Labile INRs Elderly (age >65 years) Drugs or alcohol (1 point each) Score 1 1 or or 2 Maximum 9 points Risk Factors/ Score N Number of Bleeds Bleeds per 100 Patient-Years Any Score P-Value for Trend.007 *HAS-BLED study has not yet been validated in other data sets; Score of 3 indicates high risk, and some caution and regular patient review is needed following initiation of antithrombotic therapy. INRs = international normalized ratios. Camm AJ, et al. Eur Heart J. 2010;31(19): Pisters R. Chest. 2010;138: Lip GY, et al. Am J Med. 2010;123(6):
14 Outcome/Year (%) Outcome/Year (%) Antiplatelet Therapy in AF 6 ACTIVE-W: 6706 randomized patients; trial stopped P =.0003 Clopidogrel + ASA Warfarin ACTIVE-A: 7554 randomized patients; median follow-up of 3.6 years P =.01 Clopidogrel + ASA ASA P< P =.001 P = P< Vascular Event Stroke Major Bleeding 0 Vascular Event Stroke Major Bleeding ACTIVE = AF Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. ACTIVE Investigators. Lancet. 2006;367: ACTIVE Investigators. N Engl J Med. 2009;360(20):
15 Newer Anticoagulants Warfarin, dabigatran, and rivaroxaban are FDA approved at the present time. Activated Factor X Inhibitors Apixaban Betrixaban Edoxaban (DU-176b) TAK-442 Rivaroxaban YMI 50 Direct Thrombin Inhibitors Dabigatran Etexilate AZD0837 MCC977 Warfarin Novel Vitamin K Antagonist ATI-5923 Extrinsic Pathway Activation Intrinsic Pathway Activation Factor X Activated Factor X Inhibitors Prothrombin Direct Thrombin Inhibitors Factor Xa Fibrinogen Thrombin Factor X Fibrin Ma TKW, et al. Pharmacology and Therapeutic 2010; doi; /j.pharmthera
16 Dabigatran Etexilate: Pharmacokinetics Pro-drug converted to dabigatran via hepatic microsomal carboxylesterases 7% bioavailability (not meal dependent) 80% renally excreted T 1/2 = 8-10 hours after single dose (14-17 hours after multiple dosages) Related to aptt (non-linear) and thrombin time and ecarin clotting time (both linear), but not INR
17 Percent/Year Stroke Prevention in AF Dabigatran Etexilate vs Warfarin (RE-LY) P =.003 Dabigatran 110 mg Dabigatran 150 mg Warfarin INR *P<.001 P<.001 Dabigatran 110 mg is not FDA approved for this indication; for informational purposes only P<.001 Avg TTR: 67% P<.001 P= Stroke/Systemic Embolism Major Bleed Intracranial Hemorrhage *Noninferiority; Superiority. MI = myocardial infarction; RE-LY = Randomized Evaluation of Long-term Anticoagulation Therapy. Connolly SJ, et al. N Engl J Med. 2009;361(12): Connolly SJ, et al. N Engl J Med. 2011;363: MI
18 ACCF/AHA/HRS 2011 Focused Update to the Guidelines for Antithrombotic Therapy to Prevent Stroke Risk Category No risk factors One moderate-risk factor (Age 75 yrs, HTN, CHF, LVEF 35%, and diabetes) Any high-risk factor or more than 1 moderate-risk factor (Previous stroke, TIA or embolism, mitral stenosis, and Prosthetic heart valve*) Recommended Therapy Aspirin, 81 to 325 mg daily Aspirin 81 to 325 mg daily, or Warfarin (INR 2.0 to 3.0, target 2.5) Dabigatran Warfarin (INR 2.0 to 3.0, target 2.5)* Dabigatran ESC Guidelines use CHA 2 DS 2 -VASc, rather than CHADS 2, risk stratification, with score 2 requiring warfarin or dabigatran. *If mechanical valve, target INR >2.5. Dabigatran is useful as an alternative to warfarin in patients with AF and risk factors for stroke or systemic embolization who do not have a prosthetic heart valve or hemodynamically significant valve disease, severe renal failure, or advanced liver disease. LV = left ventricular; INR = international normalized ratio; TIA = transient ischemic attack. Fuster V, et al. J Am Coll Cardiol 2006;48:e149-e246. Wann SL, et al. Heart Rhythm. 2011;8:e1-8.
19 Characteristics of New and Investigational Oral Anticoagulants Drug Dabigatran Rivaroxaban Apixaban Betrixaban Edoxaban Mechanism of action Thrombin inhibitor Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor Factor Xa inhibitor T 1/ hours 5-9 hours 12 hours hours 6-12 hours Regimen BID QD, BID BID QD QD Peak to trough Renal excretion of absorbed drug Potential for drug interactions ~7x 12x (QD) 3-5x ~3x ~3x ~80% 36%-45% 25%-30% ~15% 35% P- glycoprotein inhibitor CYP3A4 substrate and P- glycoprotein inhibitor CYP3A4 substrate and P- glycoprotein inhibitor Not substrate for major CYPs CYP3A4 substrate and P- glycoprotein inhibitor T 1/2 = half-life; CYP3A4 = cytochrome P450 3A4. Usman MH, et al. Curr Treat Cardiovasc Med. 2008;10(5): Piccini JP, et al. Curr Opin Cardiol. 2010;25(4):
20 Event Rate / 100 Pt-Yrs ROCKET AF: Primary Efficacy and Safety Outcomes Rivaroxaban* Warfarin P=0.02 On Treatment ITT Major Bleeding Intracranial Bleeding *P<0.001 for noninferiority of rivaroxaban vs warfarin; Superiority. Event rates are per 100 patient-years. Based on safety on treatment or ITT through site notification populations. Patel MR, et a. N Engl J Med Published online August 30, P=0.12 Stroke and Non-CNS Embolism P=0.58 Rivaroxaban was recently approved by the FDA for stroke prevention in AF. Safety P=0.02
21 Event Rate / 100 Pt-Yrs ARISTOTLE Trial: Efficacy and Safety Results Apixaban** Warfarin P=0.047 P < P < P= P < Stroke or Systemic Embolism Death from Any Cause ISTH Major Bleeding Intracranial Bleeding Net Clinical Outcomes* *Net clinical outcomes: Stroke, system embolism, or major bleeding. **Apixaban is not FDA approved. Granger CB, et al. N Engl J Med Published online August 30, 2011.
22 Rate vs Rhythm Control ACC/AHA/ESC Before choosing rate control as a long-term strategy, the clinician should consider how permanent AF is likely to affect the patient in the future. RACE and AFFIRM do not necessarily apply to younger patients without heart disease or to patients whose dependency upon sinus rhythm is likely to change appreciably over time. This makes it important to ensure that a window of opportunity to maintain sinus rhythm is not overlooked early in the course of management of a patient with atrial fibrillation. Fuster et al. J Am Coll Cardiol. 2006;48:
23 Cumulative Mortality (%) AFFIRM: Primary Endpoint All-Cause Mortality Rhythm control Rate control The AFFIRM Investigators. N Engl J Med. 2002;347: (A) P= Time (years) No. of deaths Number (%) Rhythm: 0 80 (4) 175 (9) 257 (13) 314 (18) 352 (24) Rate: 0 78 (4) 148 (7) 210 (11) 275 (16) 306 (21)
24 AFFIRM: On-Treatment Post Hoc SR Is Associated With Better Survival SR Warfarin -54% -47% 0.54 ( ; P<.0001) 0.47 ( ; P<.0001) Digoxin 1.50 ( ; P<.0001) +50% AADs 1.41 ( ; P=.0005) +41% Risk Ratio Other significant variables in model: age, CAD, CHF, smoking, stroke/tia, LVEF, mitral regurgitation. The AFFIRM Investigators. Circulation. 2004;109:
25 Clinical Considerations for Management Strategy of Rate Versus Duration and patterns of AF Type and severity of symptoms Associated cardiovascular disease Potential for changes in cardiac function over time Fuster et al. J Am Coll Cardiol. 2006;48:
26 Rate vs Rhythm and Physician Characteristics Assessed patient and physician characteristics associated with the choice of rate or rhythm control strategy in hospital 155,731 hospitalizations from 464 hospitals 48% rhythm control 52% rate control Care by a noncardiologist and increasing age >65 years were associated with lower odds of rhythm vs rate control (OR 0.33, 95% CI, for family, general, and internal medicine vs cardiology) Warfarin use was greater in the rhythm control group compared with the rate control group Lapointe et al. Am J Cardiol. 2008;101(8):
27 Rate Control
28 Agents for Heart Rate Control Nonacute and Chronic Maintenance Beta blockers Metoprolol Carvedilol Atenolol Calcium channel blockers Diltiazem Verapamil Digoxin Fuster et al. J Am Coll Cardiol. 2006;48:
29 What Is Adequate Rate Control? Adequate rate control is critical to avoid tachycardia-mediated cardiomyopathy beats per minute at rest AND beats per minute with exertion Criteria vary with age May be evaluated using 24-hour Holter recording Fuster et al. J Am Coll Cardiol. 2006;48:
30 RACE II 614 patients with permanent AF Lenient rate control: resting heart rate <110 bpm (97.7% met target) Strict rate control: resting heart rate <80 bpm and heart rate during moderate exercise <110 bpm (67% met target) Primary outcome: composite of death from CV causes, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and lifethreatening arrhythmic events Incidence of primary outcome at 3 years Lenient: 12.9% Strict: 14.9% Van Gelder IC et al., NEJM 2010;362:
31 RACE II The mean (±SD) resting heart rate at the end of dose-adjustment: Lenient control: 93±9 bpm in the Strict-control: 76±12 bpm (P<0.001) At the end of the follow-up period: Lenient-control: 85±14 bpm Strict-control group: 76±14 bpm (P<0.001) Van Gelder IC et al., NEJM 2010;362:
32 Rhythm Control
33 Pharmacologic Management of Patients With Recurrent Paroxysmal Atrial Fibrillation Sinus Rhythm Maintenance Recurrent Paroxysmal AF Minimal or no symptoms Disabling symptoms in AF Anticoagulation and rate control as needed Anticoagulation and rate control as needed No drug for prevention of AF Fuster et al. J Am Coll Cardiol. 2006;48: AAD therapy AF ablation if AAD treatment fails
34 2011 ACCF/AHA/HRS Guidelines: Antiarrhythmic Approaches to Maintain SR in Patients with Recurrent PAF or Persistent AF* Maintenance of SR No (or minimal) heart disease HTN CAD HF Dronedarone Flecainide Propafenone Sotalol No Substantial LVH Yes Dofetilide Dronedarone Sotalol Amiodarone Dofetilide Amiodarone Dofetilide Catheter ablation Dronedarone Flecainide Propafenone Sotalol Amiodarone Amiodarone Catheter ablation Catheter ablation Amiodarone Dofetilide Catheter ablation Catheter ablation A Safety-Driven Approach *Within each box, drugs are listed alphabetically and not in order of suggested use. ACCF/AHA/HRS = American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society; CAD = coronary artery disease; ESC = European Society of Cardiology; LVH = left ventricular hypertrophy; NYHA = New York Heart Association. Wann LS, et al. Circulation. 2011:123: Camm AJ, et al. Eur Heart J. 2010:31;
35 Outpatient Treatment of Recent-Onset Atrial Fibrillation with the Pill-in-the-Pocket Approach Flecainide 300 mg orally (200 mg for <70 kg) Propafenone 600 mg orally (450 mg for <70 kg) Treatment was successful in 534 episodes (94 percent) Time to resolution of symptoms was 113±84 minutes Among the 165 patients with recurrences, the drug was effective during all the arrhythmic episodes in 139 patients (84 percent) Alboni, P. et al., N Engl J Med 2004;351:
36 Patients in SR at 1 Year (%) Efficacy of AADs in AF Trials Amiodarone Dronedarone Sotalol Class IC Placebo CTAF SAFE-T AFFIRM DAFNE* EURIDIS* ADONIS EURIDIS/ DIONYSOS *At 6 months; Mean follow-up 7 months. ADONIS Pooled CTAF = Canadian Trial of Atrial Fibrillation; SAFE-T = Sotalol Amiodarone Atrial Fibrillation Efficacy Trial; DAFNE = Dronedarone Atrial Fibrillation Study after Electrical Cardioversion; EURIDIS = European Trial in Atrial Fibrillation or Flutter Patients Receiving Dronedarone for the Maintenance of Sinus Rhythm; ADONIS = American-Australian- African Trial with Dronedarone in Atrial Fibrillation or Flutter for the Maintenance of Sinus Rhythm; DIONYSOS = Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Dronedarone vs Amiodarone for at Least 6 Months for the Maintenance of Sinus Rhythm in Patients with AF. Courtesy of G Naccarelli, MD. Roy D, et al. Am J Cardiol. 1997;80: Singh BN, et al. N Engl J Med. 2005;352(18): AFFIRM Investigators. J Am Coll Cardiol. 2003;42: Touboul P, et al. Eur Heart J. 2003;24: Singh BN, et al. N Engl J Med. 2007;357(10): Le Heuzey JY, et al. J Cardiovasc Electrophysiol. 2010;21:
37 Dronedarone Dronedarone CH 3 SO 2 HN O O O (CH 2 ) 3 CH 3 (CH 2 ) 3 CH 3 I O(CH 2 ) 3 N (CH 2 ) 3 CH 3 (CH 2 ) 3 CH 3 De-iodinated amiodarone analog Predictable pharmacokinetics (T1/2 of hrs; BID dosing) Hepatically cleared Low incidence of side effects Amiodarone O I O(CH 2 ) 2 N CH 2 CH 3 CH 2 CH 3 Low proarrhythmia (safe to use as outpatient) No evidence of thyroid or pulmonary toxicity but rare cases of serious hepatotoxicity Kathofer S, et al. Cardiovasc Drug Rev. 2005;23(3): Hynes BJ, et al. Future Cardiol. 2005;1(2): US Food and Drug Administration. Accessed March 10, 2011.
38 Dronedarone: Pharmacological Effects Na channel blocker (10X stronger than amiodarone) Antiadrenergic effect (non-competitive βrc binding) Potassium channel blocker (I Kr ; I Ks ; I Ach-Ado ; I K1 ); (I Ach-Ado 100X stronger than amiodarone) Calcium channel blocker (I Ca-L ) Special considerations and contraindications Contraindicated in Class IV HF or lesser HF with recent decompensation Potential liver toxicity/hepatic function impairment Drug interactions similar to amiodarone, except no significant interaction with warfarin Exposure to dabigatran is higher when it is administered with dronedarone Should not be used in permanent AF Patel C, et al. Circulation. 2009;120: Multaq [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; 2011.
39 Cumulative Incidence (%) ATHENA Primary Outcome: First Cardiovascular Hospitalization or Death Primary End Point: Reduction in CV Hospitalization or Death From Any Cause (Entirely Attributable to Effect on CV Hospitalization) Placebo Dronedarone 24% RRR HR=0.76 (95% CI: ) P< Months Patients at Risk Placebo Dronedarone Components of End Point (as First Event) Placebo (n=2327) n (%) Mean follow-up 21± 5 months. RRR = relative risk reduction. Hohnloser SH, et al. N Engl J Med. 2009;360: Dronedarone 400 mg BID (n=2301) n (%) CV hospitalization 856 (36.8) 669 (29.1) Death from any cause 57 (2.4) 58 (2.5)
40 ANDROMEDA: Study Primary Endpoint Primary endpoint The primary composite endpoint was all-cause mortality Results or hospitalization for heart failure vs placebo Analysis up to study discontinuation Placebo (n=317) Dronedarone 800 mg/d (n=310) Number of patients who died Relative risk (relative to placebo) % CI 1.071, P value The excess in mortality was primarily related to an excess of heart failure related deaths. CI = confidence interval. Kober L, et al. NEJM 2008;358;
41 PALLAS Study Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy Hypothesis Dronedarone would reduce major vascular events in high-risk permanent atrial fibrillation Methods/Inclusion criteria Patients > 65 years of age > 6-month history of permanent atrial fibrillation Risk factors for major vascular events Patients randomized to dronedarone 400 mg bid vs. placebo Coprimary outcomes Stroke, MI, systemic embolism or CV death Unplanned CV hospitalization or death Connolly, SJ et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011; DOI: /NEJMoa Published Nov 14, Accessed Nov 15, 2011.
42 Rate per 100 Patient-Years PALLAS Trial: Dronedarone in Permanent AF After PALLAS enrolled 3236 patients, the study was stopped for safety reasons. P< Dronedarone Placebo P< P= Stroke, MI, Systemic Embolism, or CVD 12.9 Death or Unplanned CV Hospitalization Connolly, SJ et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011; DOI: /NEJMoa Published Nov 14, Accessed Nov 15, P=0.049 P= P= Death Stroke Hospitalization for HF 10.7 HF Episode or Hospitalization
43 CATHETER ABLATION
44 2011 ACCF/AHA/HRS Guidelines: Catheter Ablation is Still Second Tier Therapy Maintenance of SR No (or minimal) heart disease HTN CAD HF Dronedarone Flecainide Propafenone Sotalol No Substantial LVH Yes Dofetilide Dronedarone Sotalol Amiodarone Dofetilide Amiodarone Dofetilide Catheter ablation Dronedarone Flecainide Propafenone Sotalol Amiodarone Amiodarone Catheter ablation Catheter ablation Amiodarone Dofetilide Catheter ablation Catheter ablation A Safety-Driven Approach ACCF/AHA/HRS = American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society; CAD = coronary artery disease; ESC = European Society of Cardiology; LVH = left ventricular hypertrophy; NYHA = New York Heart Association. Wann LS, et al. Circulation. 2011:123: Camm AJ, et al. Eur Heart J. 2010:31;
45 Indications for Catheter AF Ablation Symptomatic AF refractory or intolerant to at least 1 Class I or III AAD Selected symptomatic patients with HF and/or reduced ejection fraction As an alternative to device implantation to support AAD therapy in bradycardic patients Presence of an LA thrombus is a contraindication to catheter ablation of AF Discontinuation of anticoagulation is not an indication for ablation Calkins H, et al. Heart Rhythm. 2007;4(6):
46 Meta-Analysis of Catheter Ablation vs Drug Therapy Statistics for Each Study Risk Lower Upper Study Name Ratio Limit Limit Z P Risk Ratio and 95% CI Thai study Natale et al APAF study CACAF study Haissaguerre et al Morady et al APAF = Ablation for Paroxysmal Atrial Fibrillation; CACAF = Catheter Ablation for the Cure of Atrial Fibrillation. Nair GM, et al. J Cardiovasc Electrophysiol. 2009;20(2): Favors Ablation Favors Medical Therapy
47 Rates (%) Success Rates With Ablation Worldwide Survey Success without AADs Success with AADs Overall success >24 Range of followup (months) Cappato et al. Circulation. 2005;111: (B).
48 LV End-Diastolic Diameter (mm) LV Ejection Fraction (%) LV Ejection Fraction (%) LV Ejection Fraction (%) Effect of AF Ablation on LVEF and Chamber Size in Patient with and without Concurrent Heart Disease and Rate Control P < Ejection Fraction P < Months P < P < Heart Disease No Concurrent Heart Disease Concurrent Heart Disease 0 12 Months P < P < P=0.001 LV ED Diameter P= Months Hsu LF, et al. NEJM 2004; 351: P=0.02 P= Rate Control Inadequate Rate Control Adequate Rate Control Months 12 P < P < 0.001
49 Patients (%) Complication Rates for Catheter Ablation Cappato et al. Circulation. 2005;111: (B)
50 CABANA Trial Recent-onset AF eligible for ablation or drug therapy 65 years old or < 65 years old with 1 risk factor for CAD or stroke Primary Ablation (technique at operator discretion) Drug Therapy (rate or rhythm control [at operator discretion] with anticoagulation) Discontinued Anticoagulation Continued Anticoagulation Packer. Presented at: 2005 Scientific Sessions of the American Heart Association; November 13-16, 2005; Dallas, TX(A i ).
51 Summary AF is a common disease that is increasing in prevalence. Atrial electrical and structural remodeling takes place early and progresses, making the return to SR more difficult with longer duration of AF. Newer anticoagulants provide more options for stroke prophylaxis in patients with AF Decisions about rate and rhythm control in AF depend on the frequency of episodes and the severity of patients symptoms. Catheter ablation is curative in many patients who have failed antiarrhythmic drug therapy.
52 Post-Test Question #1. A 69 year old Caucasian female is referred from her primary care physician s office after she presented with episodic palpitations and was found to have new onset atrial fibrillation. She has a past medical history of hypertension that is well controlled with lisinopril 10 mg daily. There is no history of diabetes mellitus, prior stroke or transient ischemic attack, or cardiovascular disease. What are her CHADS 2 and the CHA 2 DS 2 -VASc scores? a) 1 and 1 b) 1 and 2 c) 1 and 3 d) 1 and 4 CHADS 2 score of 1: Hypertension CHA 2 DS 2 -VASc score of 3: hypertension, female, and age between 65 to 74 years
53 Post-Test Question #2. What anti-thrombotic therapy would you initiate to prevent a risk of stroke in this patient? a) None, her risk for stroke is low b) Aspirin 325 mg daily c) Aspirin 325 mg + clopidogrel 75 mg daily d) Warfarin to maintain a therapeutic INR between 2 and 3 Although her CHADS 2 score is 1, her CHA 2 DS 2 - VASc score is 3. This gives her a stroke risk of 3.2%, that is best minimized with warfarin.
54 Post-Test Question #3. A 73 year old patient is referred for preoperative evaluation for knee replacement surgery because her ECG showed previously undiagnosed atrial fibrillation. She denies cardiovascular symptoms, but she has treated hypertension and a history of myocardial infarction. There is no history of diabetes mellitus, stroke or TIA, or bleeding problems. She denies illicit drug or alcohol use. Her weight is 92.7 kg, Her serum creatinine is 3.2 mg/dl and estimated creatinine clearance is 14 ml/min; liver function is normal. The ECG shows AF with an average ventricular rate of 75 bpm. Echocardiogram shows left ventricular hypertrophy and left atrial enlargement.
55 Which anticoagulation strategy would you recommend? a) Aspirin b) Warfarin c) Dabigatran d) Rivaroxaban Both dabigatran and rivaroxaban are cleared by the kidneys and should be avoided when creatinine clearance is less than 15 ml/min.
Atrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationDronedarone: Need to Perform a CV Outcome Safety Study
Dronedarone: Need to Perform a CV Outcome Safety Study Gerald V. Naccarelli M.D. Consultant: Glaxo-Smith-Kline, Pfizer, Sanofi, Boehringer-Ingelheim, Daiichi-Sankyo, Bristol Myers Squibb, Otsuka, Janssen
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More informationRate and Rhythm Control of Atrial Fibrillation
Rate and Rhythm Control of Atrial Fibrillation April 21, 2017 춘계심혈관통합학술대회 Jaemin Shim, MD, PhD Arrhythmia Center Korea University Anam Hospital Treatment of AF Goal Reducing symptoms Preventing complication
More informationRate or Rhythm Control? Epidemiology. Relevant Advances in Atrial Fibrillation 6/20/2011. Stroke Prophylaxis
Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Managing Atrial Fibrillation: Tips for the Generalist Antiarrhythmic Drug Therapy Ablation Gregory M Marcus, MD, MAS Assistant Professor of Medicine
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationPractical Rate and Rhythm Management of Atrial Fibrillation
Practical Rate and Rhythm Management of Atrial Fibrillation pocket guide UPDATED FEBRUARY 2013 Adapted from the ACCF/AHA/HRS 2011 Focused Updates Incorporated into the ACC/AHA/ESC Guidelines for the Management
More informationUnderstanding Atrial Fibrillation Management. Roy Lin, MD
Understanding Atrial Fibrillation Management Roy Lin, MD Disclosure None Definition of atrial fibrillation Atrial fibrillation is a supraventricular tachyarrhythmia characterized by uncoordinated atrial
More informationUC SF. Division of General Internal Medicine UNIVERSITY OF CALIFORNIA SAN FRANCISCO, DIVISION OF HOSPITAL MEDICINE
Updates in the Management of Atrial Fibrillation Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical Director, Anticoagulation Clinic UC SF Division of
More informationUpdate in the Management of Atrial Fibrillation
Update in the Management of Atrial Fibrillation Gregory M Marcus, MD, MAS Associate Professor of Medicine Division of Cardiology University of California, San Francisco Disclosures Research: Gilead, Medtronic,
More informationStuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med
Stuart Beldner, MD, FHRS Assistant Professor NSLIJ Hofstra School of Med None There s no reason to panic. While it is true that one of the crew members is ill, slightly. Absence of discrete P waves Chaotic
More informationRelevant Advances in Atrial Fibrillation
Gregory M Marcus, MD, MAS Assistant Professor of Medicine Division of Cardiology University of California, San Francisco Relevant Advances in Atrial Fibrillation Stroke Prophylaxis Antiarrhythmic Drug
More informationDebate PRO. Dronedarone is an important drug in the management of paroxysmal atrial fibrillation. John Camm
ESC ICM - Internationales Congress Center München 2012 Atrial Fibrillation Controversies in Medical Treatment Debate Dronedarone is an important drug in the management of paroxysmal atrial fibrillation
More informationConflicts of Interests
Advances in the Management of Atrial Fibrillation State of the Art in 2013 Overview of AF Stroke risk and anticoagulation Rate control Antiarrhythmic Drug Therapy Catheter ablation Conclusion Hugh Calkins
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationHalf Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital
Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationSamer Nasr, M.D. Mount Lebanon Hospital.
Samer Nasr, M.D. Mount Lebanon Hospital. Lone atrial fibrillation: Younger than 60 years old. No clinical or echo evidence of cardiopulmonary disease. Favorable prognosis. Thromboembolism usually not
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationUpdate on Dronedarone and Cardiovascular Outcomes
Update on and Cardiovascular Outcomes Dr. Stuart Connolly MD McMaster University Hamilton Ontario Disclosure: Research grants, speaker fees and consulting honoraria from sanofi aventis has key structural
More informationAtrial Fibrillation and Heart Failure: A Cause or a Consequence
Atrial Fibrillation and Heart Failure: A Cause or a Consequence Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania November
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationBasics of Atrial Fibrillation. By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY
Basics of Atrial Fibrillation By Mini Thannikal NP-BC Mount Sinai St Luke s Hospital New York, NY Atrial Fibrillation(AF) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation
More informationHeart Failure, AF and Anticoagulation : Navigating the new options
Michael D. Ezekowitz, MBChB, DPhil, FACC, FAHA, FRCP, MA Professor, Thomas Jefferson Medical, Cardiovascular Research Foundation NY Lankenau Hospital Wynnewood, Pennsylvania Heart Failure, AF and Anticoagulation
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationCurrent Guideline for AF Treatment. Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine
Current Guideline for AF Treatment Young Keun On, MD, PhD, FHRS Samsung Medical Center Sungkyunkwan University School of Medicine Case 1 59 year-old lady Sudden palpitation and breathlessness for 12 hours
More informationDronedarone in the Post-Pallas Era. Jorge E. Schliamser, MD Carmel Medical Center Haifa
Dronedarone in the Post-Pallas Era Jorge E. Schliamser, MD Carmel Medical Center Haifa Disclosures None Dronedarone is a multichannel blocker Dronedarone possesses electrophysiologic characteristics of
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationDysrhythmias 11/7/2017. Disclosures. 3 reasons to evaluate and treat dysrhythmias. None. Eliminate symptoms and improve hemodynamics
Dysrhythmias CYDNEY STEWART MD, FACC NOVEMBER 3, 2017 Disclosures None 3 reasons to evaluate and treat dysrhythmias Eliminate symptoms and improve hemodynamics Prevent imminent death/hemodynamic compromise
More informationManagement of atrial fibrillation a holistic view - Prof. Dr. Martin Borggrefe Mannheim
a holistic view - Prof. Dr. Martin Borggrefe Mannheim Patients with atrial fibrillation (millions) 16 14 12 10 8 6 4 2 0 Management of atrial fibrillation Expected prevalence of apparent AF 5,1 5,1 5,9
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationAF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?!
AF#in#pa(ents#with#CAD# Is#dronedarone#a#good#choice?! DRUG#PROPHYLAXIS#OF#AF:# FOCUS#ON#DRONEDARONE# Friday#16C10C2015# Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationSubclinical AF: Implications of device based episodes
Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationOut with the old, in with The 2010 Atrial Fibrillation Guidelines
Out with the old, in with The 2010 Atrial Fibrillation Guidelines Kseniya Chernushkin B.Sc.(Pharm.), VCH/PHC Pharmacy Resident Mary Elliot B.Sc.(Pharm.), VCH/PHC Pharmacy Resident March 22, 2011 Outline
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationInnovations in AF Management
Innovations in AF Management Barry Boilson MD PhD FRCPI boilson.barry@mayo.edu Disclosures Relevant None financial relationship(s) with industry None Off Label Usage None Overview Mechanisms of AF AF as
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationLessons from recent antithrombotic studies and trials in atrial fibrillation
Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala Disclosures for Lars Wallentin
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationDr Chris Ellis. Consultant Cardiologist Auckland City Hospital Auckland
Dr Chris Ellis Consultant Cardiologist Auckland City Hospital Auckland 8:30-9:25 WS #189: Anticoagulation in AF 9:35-10:30 WS #201: Anticoagulation in AF (Repeated) Anticoagulation in Atrial Fibrillation
More informationModern management of atrial fibrillation, from blood pressure control to anticoagulation
Modern management of atrial fibrillation, from blood pressure control to anticoagulation Adel Khalifa S. Hamad, BMS, MD, FRCP(Canada) Consultant Cardiologist & Interventional Cardiac Electrophysiologist
More informationFibs and Flutters: The Heart of the Matter
Fibs and Flutters: The Heart of the Matter Anita Ralstin, CNP By the Numbers Atrial Fibrillation Hospital Discharges /quarter for 2012 -- 116,500 Average Length of Stay 4 days Projected that 20% of those
More informationABLATION OF CHRONIC AF
ABLATION OF CHRONIC AF A PISAPIA ST JOSEPH HOSPITAL MARSEILLE MEET 2008 Atrial Fibrillation The most common significant heart rhythm disturbance Incidence increases with age and the development of structural
More informationObjectives for Technicians. Objectives for Pharmacists. Pathophysiology. Conflict of Interest. Atrial Fibrillation
Warfar IN or Warfar-OUT? And Other Updates in the Management of Atrial Fibrillation Kimberly Ackerbauer, PharmD, BCPS Clinical Pharmacy Specialist Rush University Medical Center Conflict of Interest I
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationHypertension and Atrial Fibrillation in 2017
Boma Inn, Eldoret, 24th 25thFebruary 2017 Hypertension and Atrial Fibrillation in 2017 Dr Mzee Ngunga Consultant Cardiologist Aga Khan University Hospital, Nairobi Objectives 1. Understand the relationship
More informationdronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd
dronedarone, 400mg, film-coated tablets (Multaq ) SMC No. (636/10) Sanofi-aventis Ltd 6 August 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationDronedarone( What%is%the%future?!
Dronedarone( What%is%the%future?! DRUG(PROPHYLAXIS(OF(AF:( FOCUS(ON(DRONEDARONE( Friday(16>10>2015( Harry%JGM%Crijns% Maastricht,%The%Netherlands% Disclosures Harry Crijns - research grants, consulting
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationTreatment of Atrial Fibrillation in Heart Failure
Stockholm, September 1st 2010 Treatment of Atrial Fibrillation in Heart Failure Rhythm control: Which drugs? Stefan H. Hohnloser J.W. Goethe University Frankfurt, Germany Presenter disclosure information:
More informationAF and arrhythmia management. Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire
AF and arrhythmia management Dr Rhys Beynon Consultant Cardiologist and Electrophysiologist University Hospital of North Staffordshire Atrial fibrillation Paroxysmal AF recurrent AF (>2 episodes) that
More informationESC. Update of the ESC Guidelines on Medical Therapy. John Camm. ICM Internationales Congress Center München
ESC 2012 ICM Internationales Congress Center München Update on Consensus Statements on Management of Atrial Fibrillation European Heart Rhythm Association Update of the ESC Guidelines on Medical Therapy
More informationModest Medtronic. Modest Boehringer Ingelheim
Adults With AF (millions) Modest Medtronic Modest Boehringer Ingelheim Changing Modalities of Care for Atrial Fibrillation Jill Repoley MSN, CRNP, CCDS, CEPS, FHRS 7 6 5 4 3 2 1 2.08 2.26 2.44 2.66 2.94
More informationAtrial fibrillation and advanced age
Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients
More informationIn Whom and When Should Atrial Fibrillation Ablation be Considered?
In Whom and When Should Atrial Fibrillation Ablation be Considered? Christian de Chillou, MD, PhD Department of Cardiology University Hospital Nancy, France ESC 2010 Stockholm, August 30. 2010 2 In Whom?
More informationNational Horizon Scanning Centre. Dronedarone (Multaq) for atrial fibrillation and atrial flutter. December 2007
Dronedarone (Multaq) for atrial fibrillation and atrial flutter December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationDigoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?
Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter? Renato D. Lopes, MD, PhD, FACC on behalf of the ARISTOTLE Investigators
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Tuesday, April 13, 21 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationPrepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution
Prepared by Pfizer-BMS alliance in response to an unsolicited request Not for further distribution AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document
More informationAF review. Petr Polasek
AF review Petr Polasek Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic,
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationFred Kusumoto Professor of Medicine
Fred Kusumoto Professor of Medicine Faculty photo will be placed here Kusumoto.Fred@mayo.edu 2015 MFMER 3543652-1 Atrial Fibrillation Presentation Subtitle Here Mayo School of Continuous Professional Development
More informationLa terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO
La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent
More informationAre Drugs Better? Dr Mauro Lencioni. Drugs or ablation as first line treatment for AF? Consultant Cardiologist & Electrophysiologist
Are Drugs Better? Drugs or ablation as first line treatment for AF? Dr Mauro Lencioni Consultant Cardiologist & Electrophysiologist The Philosophical Issue What do we mean by Better? Outcome measures Measurement
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationNon-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices Faculty John M. Wharton, MD Frank P. Tourville Professor of Medicine Director, Cardiac Electrophysiology Medical
More informationNon-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices
Non-Valvular Atrial Fibrillation: Reducing Risk and Individualizing Therapeutic Choices John M. Wharton, MD Frank P. Tourville Professor of Medicine Director, Cardiac Electrophysiology Medical University
More informationDronedarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward?
Dronedarone For Atrial Fibrillation: Unbridled Enthusiasm Or Just Another Small Step Forward? James A. Reiffel, M.D. Introduction In July 2009, the federal Food and Drug Administration (FDA) approved the
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationSaudi Heart Association February 22, 2011
Pharmacological Therapy of Atrial Fibrillation: Recent Advances Dr Martin Green Professor of Medicine (Cardiology) University of Ottawa Saudi Heart Association February 22, 2011 Atrial Fibrillation Drugs
More informationMANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017
MANAGING ATRIAL FIBRILLATION: BEYOND ANTICOAGULATION December 9, 2017 1 Faculty Disclosure Faculty: Peter Leong-Sit MSc, MD, FRCPC, FHRS Associate Professor, Western University Cardiologist, London Heart
More informationAtrial Fibrillation Management in the ED. J Fisher May 2014"
Atrial Fibrillation Management in the ED J Fisher May 2014" A 48 yr old man presents with palpitations. He had a big night last night with old mates. ECG How will you manage him? Why important? Common
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationAtrial Fibrillation Etiologies and Treatment. Shawn Liu Learner Centered Learning Goal
Atrial Fibrillation Etiologies and Treatment Shawn Liu Learner Centered Learning Goal Pathophysiology Defined by the absence of coordinated atrial systole Results from multiple reentrant electrical waves
More informationIs Apixaban Effective for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2014 Is Apixaban Effective for the Prevention
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationRecent observations have focused attention on the PVs as a source of ectopic activity i determining i AF
Atrial Fibrillation in 2010 Panos Vardas Professor of Cardiology President of EHRA Atrial Fibrillation Pathophysiology of AF Triggers Recent observations have focused attention on the PVs as a source of
More informationAtrial Fibrillation in the Emergency Department
Atrial Fibrillation in the Emergency Department Disclosures Edward Jauch, MD MS Research support National Institutes of Health funding (multiple trials) Novo Nordisk (drug in kind) STOP-IT Study Genentech
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationManaging Atrial Fibrillation in the Heart Failure Patient
Managing Atrial Fibrillation in the Heart Failure Patient Jonathan S. Steinberg, MD Professor of Medicine (adj) University of Rochester School of Medicine & Dentistry Director, Arrhythmia Institute Valley
More informationManagement of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39
Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationAtrial Fibrillation What are the Options in 2016?
Atrial Fibrillation What are the Options in 2016? David Spragg, MD, FHRS Johns Hopkins Hospital Cardiovascular Disease Management October, 2016 Disclosures Consulting, Biosense Webster Overview What is
More information